Brief Communication: Temporal Trends of Chronic Diseases Medications Prescriptions Among HIV-infected Patients in Belgium: a 4-year Population-based Study Using Pharmacy Claims Data

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Jul 27

PMID 39068430

Authors

Dieudonne Ilboudo

Calypse Ngwasiri

Isabelle Savoye

Agnes Sommet

Dominique Van Beckhoven

Jean Cyr Yombi

Fati Kirakoya-Samadoulougou

Affiliations

Soon will be listed here.

Abstract

The Objective of this study was to examine change over time of prevalence of chronic diseases medications (CDM) prescriptions among People living with HIV (PLWH) in Belgium, using Pharmanet database from 2018 to 2021. We identified 13,570, 14,175, 14,588 and 14,813 PLWH in 2018, 2019, 2020 and 2021, respectively. Prescriptions of cardiovascular diseases (CVD) medications (31.7-37.2%) and antidiabetics (7.4-9.0%), increased significantly (p for trend < 0.001 for all), while the prescription of neurological and mental disorders medications (18.0-19.3%) remained stable (p for trend = 0.11) and the prescription of chronic respiratory diseases (CRD) medications decreased from 12.2 to 10.6% (p for trend < 0.001), between 2018 and 2021. It is imperative to ensure that these medications are used appropriately.

References

Okoli C, Schwenk A, Radford M, Myland M, Taylor S, Darley A . Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database. HIV Med. 2020; 21(8):471-480. PMC: 7497154. DOI: 10.1111/hiv.12879. View

. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017; 4(8):e349-e356. PMC: 5555438. DOI: 10.1016/S2352-3018(17)30066-8. View

Back D, Marzolini C . The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020; 23(2):e25449. PMC: 6996317. DOI: 10.1002/jia2.25449. View

Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, van Sighem A . Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015; 15(7):810-8. PMC: 4528076. DOI: 10.1016/S1473-3099(15)00056-0. View

Bigna J, Kenne A, Asangbeh S, Sibetcheu A . Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. Lancet Glob Health. 2017; 6(2):e193-e202. DOI: 10.1016/S2214-109X(17)30451-5. View

Pelchen-Matthews A, Ryom L, Borges A, Edwards S, Duvivier C, Stephan C . Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. AIDS. 2018; 32(16):2405-2416. DOI: 10.1097/QAD.0000000000001967. View

Lee K, Ang C, Lim S, Siau C, Ong L, Ching S . Prevalence of mental health conditions among people living with HIV during the COVID-19 pandemic: A rapid systematic review and meta-analysis. HIV Med. 2022; 23(9):990-1001. PMC: 9111307. DOI: 10.1111/hiv.13299. View

Gutierrez-Abejon E, Criado-Espegel P, Herrera-Gomez F, Alvarez F . Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving. Pharmaceuticals (Basel). 2020; 13(8). PMC: 7464462. DOI: 10.3390/ph13080165. View

Anderson T, Ayanian J, Zaslavsky A, Souza J, Landon B . National Trends in Antihypertensive Treatment Among Older Adults by Race and Presence of Comorbidity, 2008 to 2017. J Gen Intern Med. 2022; 37(16):4223-4232. PMC: 9708992. DOI: 10.1007/s11606-022-07612-3. View

10.

Leung J . HIV and chronic lung disease. Curr Opin HIV AIDS. 2023; 18(2):93-101. DOI: 10.1097/COH.0000000000000777. View

11.

Gunter J, Callens S, De Wit S, Goffard J, Moutschen M, Darcis G . Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study. Acta Clin Belg. 2017; 73(1):50-53. DOI: 10.1080/17843286.2017.1339965. View

12.

Rasmussen L, Obel D, Kronborg G, Larsen C, Pedersen C, Gerstoft J . Utilization of psychotropic drugs prescribed to persons with and without HIV infection: a Danish nationwide population-based cohort study. HIV Med. 2014; 15(8):458-69. DOI: 10.1111/hiv.12135. View

13.

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

14.

Moussaoui M, Lambert I, Maes N, Sauvage A, Frippiat F, Meuris C . Evolution of Drug Interactions With Antiretroviral Medication in People With HIV. Open Forum Infect Dis. 2020; 7(11):ofaa416. PMC: 7651038. DOI: 10.1093/ofid/ofaa416. View

15.

Jespersen N, Axelsen F, Dollerup J, Norgaard M, Larsen C . The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era. HIV Med. 2021; 22(6):478-490. PMC: 8247855. DOI: 10.1111/hiv.13077. View